Possible predictive biomarkers for tumor response to mTOR inhibitors, as are actually explained in glioblastoma, breast and prostate cancer cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] As a result, this facts is based on preclinical assays, according to in vitro cultured tumor mobile https://xp-5943210.widblog.com/83539632/5-essential-elements-for-tussilagone